XML 78 R51.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Summary of Revenue Recognized under Various Agreements (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2014 | Sep. 30, 2014 | Jun. 30, 2014 | Mar. 31, 2014 | Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue | $ 8,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized |  |  | $ 5,400 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized |  |  |  |  |  |  |  | $ 3,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Total revenues | 2,277 us-gaap_Revenues | 2,209 us-gaap_Revenues | 3,048 us-gaap_Revenues | 3,498 us-gaap_Revenues | 2,847 us-gaap_Revenues | 2,927 us-gaap_Revenues | 3,392 us-gaap_Revenues | 2,085 us-gaap_Revenues | 11,032 us-gaap_Revenues | 11,251 us-gaap_Revenues | 9,714 us-gaap_Revenues |
Grant revenue |  |  |  |  |  |  |  |  | 2,688 us-gaap_RevenueFromGrants | 5,138 us-gaap_RevenueFromGrants | 3,939 us-gaap_RevenueFromGrants |
National Institutes Of Health |  |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  |  |  | 593 us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember | 1,035 us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember | 368 us-gaap_RevenueFromGrants / us-gaap_TypeOfArrangementAxis = dvax_NationalInstitutesOfHealthMember |
Astra Zeneca |  |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Initial payment |  |  |  |  |  |  |  |  | 681 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 720 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 720 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |
Subsequent payment |  |  |  |  |  |  |  |  | 2,554 dvax_SubsequentPayment / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |  |  |
Milestone revenue |  |  |  |  |  |  |  |  | 2,174 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 2,507 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 2,462 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |
Total revenues |  |  |  |  |  |  |  |  | 5,409 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 3,227 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember | 3,182 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_AstraZenecaMember |
Glaxo Smith Kline |  |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Initial payment |  |  |  |  |  |  |  |  | 2,524 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember | 1,702 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember | 1,428 us-gaap_DeferredRevenueAdditions / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember |
Total revenues |  |  |  |  |  |  |  |  | 2,524 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember | 1,702 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember | 1,428 us-gaap_Revenues / us-gaap_CounterpartyNameAxis = dvax_GlaxoSmithKlineMember |
National Institute Of Allergy And Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Grant revenue |  |  |  |  |  |  |  |  | $ 2,095 us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember | $ 4,103 us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember | $ 3,571 us-gaap_RevenueFromGrants / us-gaap_CounterpartyNameAxis = dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember |

X
- Definition Subsequent payment. + References No definition available. + Details
Name: | dvax_SubsequentPayment
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueFromGrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=dvax_NationalInstituteOfAllergyAndInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |